Dasatinib N-oxide-d8

This product is currently out of stock and unavailable.

Products Details

Product Description

– Dasatinib N-oxide-d8 is the deuterium labeled Dasatinib N-oxide. Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor[1][2].

Web ID

– HY-133794S

Shipping

– Room temperature

Molecular Formula

– C22H18D8ClN7O3S

References

– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Christopher LJ, et, al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008 Jul;36(7):1357-64.|[3]Furlong MT, et, al. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2012 Jan 25;58:130-5.

CAS Number

– 1189988-36-0

Molecular Weight

– 512.05

SMILES

– OCC[N+]1([O-])C([2H])([2H])C([2H])([2H])N(C2=NC(C)=NC(NC3=NC=C(C(NC4=C(C)C=CC=C4Cl)=O)S3)=C2)C([2H])([2H])C1([2H])[2H]

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– 10 mM in DMSO

Target

– Drug Metabolite;Isotope-Labeled Compounds

Pathway

– Metabolic Enzyme/Protease;Others

Product type

– Isotope-Labeled Compounds

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=